Although there have been several advancements in breast cancer treatment, middle and low-income countries still have high mortality rates. To learn more about how breast cancer care can be improved on a global level, Mario Nacinovich is joined by Dr. Ben Anderson, Director of the Breast Health Global Initiative at the Fred Hutchinson Cancer Research Center.

With the latest research findings highlighted at the 2020 ASCO Annual Meeting in mind, it’s clear that there’s a new horizon opening for the breast cancer era. However, there are still some challenges that we need to address as a field, as Dr. Bora Lim explains.

Join Dr. Bora Lim, Assistant Professor in the Department of Breast Medical Oncology at the University of Texas MD Anderson Cancer Center, as she shares details and key findings of the PADA-1 trial.

The ASCO Annual Meeting highlights the latest research in oncology, and joining Mario Nacinovich to share her insights on the KEYNOTE-355, BYLieve, PARSIFAL, and MINDACT trials investigating evolving treatment options for breast cancer is Dr. Bora Lim, Assistant Professor in the Department of Breast Medical Oncology at the University of Texas MD Anderson Cancer Center.

Joining Dr. Jennifer Caudle to catch us up to speed on the latest research to come out of the 2020 ASCO Annual Meeting is Dr. David Page, medical oncologist at Providence Cancer Center in Portland, Oregon. Together, they’ll review the results from various trials investigating the use of immunotherapy for triple-negative breast cancer, including the KEYNOTE-355, ENHANCE-1, and ENCORE 602 trials.

There are several new strategies that have been emerging to treat patients with HER2+ breast cancer, and here to walk us through those that were highlighted at the 2020 ASCO Annual Meeting is Dr. Sara Tolaney, breast medical oncologist at the Dana-Farber Cancer Institute and Assistant Professor of Medicine at the Harvard Medical School.

What do we know now about the potential safety and tolerability of administering T-DM1 with pembrolizumab to patients with HER2+ breast cancer? Breast medical oncologist at the Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School Dr. Sara Tolaney explains these findings from her study that was presented at the 2020 ASCO Annual Meeting.

Triple-negative breast cancer comprises up to 20 percent of all breast cancer diagnoses, and unfortunately, survival for these patients has been more limited than in other subtypes of disease. That’s why improving outcomes for patients with triple-negative breast cancer has been the focus of recent studies—much like the one investigating eribulin and pembrolizumab that Dr. Sara Tolaney, breast medical oncologist at the Dana-Farber Cancer Institute, presented at the 2020 ASCO Annual Meeting.

One of the biggest challenges facing oncologists was the lack of standardized treatment practices for patients with hereditary breast cancers. But now that representatives from three major oncology societies have met to remedy that issue, Dr. Anthony Dragun from the MD Anderson Cancer Center at Cooper University Hospital joins us to review the latest recommendations.

Open communication can greatly impact how a patient is able to cope with the difficult emotions that often accompany a breast cancer diagnosis. Joining us to share how her own experience of being a physician-turned-caregiver for her father who was diagnosed with cancer influenced her own approach to counseling patients is Dr. Stephanie Graff, Director of the Breast Cancer Program for the Sarah Cannon Cancer Institute.